Poster shows how Cytox platform can support drug development in multiple populations

14th July 2019: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, rapid, risk assessment and patient stratification tools for Alzheimer's disease and dementia, will make a poster presentation today at the Alzheimer's Association Internation Conference (AAIC 2019).

The poster (displayed from 1.00pm at #P1-532) is titled: Polygenic Risk Score Distributions of Alzheimer’s Disease Within Different Populations. While the utility of Polygenic Risk Score (PRS) is gaining increasing attention for estimating individual genetic risk profile and disease risk prediction in Alzheimer’s Disease (AD), its accuracy depends on the discovery cohort. With the majority of PRS studies conducted in European-ancestry populations, PRS analysis among different ancestries loses accuracy. In this study we aimed to assess the differences in AD PRS estimates due to the differences in linkage-disequilibrium and allele frequencies in European, East-Asia and Africa populations..

Richard Pither, CEO of Cytox, said: “The genetics of Alzheimer’s Disease varies across populations with different ancestry. This latest research builds our PRS-based products, genoSCORE and genoTOR, towards supporting the development of new Alzheimer’s drugs that can address the genetic nuances of the disease in different populations. Our rapid tests that use either blood or saliva samples, are now available on a fee for service basis, through a licensing agreement, or as part of a strategic partnership to develop companion diagnostics for future drugs.”

Please visit the Cytox AAIC booth in the conference exhibition hall (#202).

References:

1. World Alzheimer’s Report 2015 www.alz.co.uk/research/WorldAlzheimerReport2015.pdf